{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:43:25Z","timestamp":1790621005430,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2021,4,8]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Patients with short bowel syndrome (SBS) and colon in continuity have better adaptation potential compared with patients with jejunostomy. Adaptation may involve enhanced postprandial secretion of the enteroendocrine hormones glucagon-like peptide (GLP)-1 and GLP-2 which are normally degraded by dipeptidyl peptidase (DPP)-4. Nevertheless, some patients with SBS with colon in continuity suffer from high-volume faecal excretions and have been shown to benefit from treatment with GLP-2. Therefore, we aimed to evaluate efficacy of sitagliptin, a DPP-4 inhibitor, on reducing faecal excretions in this patient group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>In an open-label, case series, proof-of-concept pilot study, 100\u2009mg oral sitagliptin was given two times per day for 8\u2009weeks to patients with SBS with \u226550% colon in continuity with or without the need for parenteral support (PS). To assess intestinal function, metabolic balance studies were done at baseline and following 8\u2009weeks of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 10 patients planned for enrolment, 8 patients were included; 7 patients completed the study. Although postprandial endogenous GLP-2 concentrations increased by 49\u2009hours\u00d7pmol\/L (39, 105; p=0.018) (median (min, max)), sitagliptin did not significantly reduce median faecal wet weight (\u2212174\u2009g\/day (\u22121510, 675; p=0.176)) or increase intestinal wet weight absorption. However, heterogeneity in the treatment effect was observed: intestinal wet weight absorption increased in all four patients with intestinal failure. One patient achieved a reduction in PS by 500\u2009mL per administration day.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Following this negative, small pilot study, larger, placebo-controlled, studies are needed to establish the therapeutic potential of DPP-4 inhibition in patients with SBS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2021-000604","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T12:38:41Z","timestamp":1620736721000},"page":"e000604","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-9234","authenticated-orcid":false,"given":"Rahim Mohammad","family":"Naimi","sequence":"first","affiliation":[{"name":"Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Krogh","family":"Hvistendahl","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Margrete","family":"Thomassen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Bayer","family":"Christiansen","sequence":"additional","affiliation":[{"name":"NNF Centre for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"NNF Centre for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[{"name":"NNF Centre for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle Bekker","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"2025073013012278000_8.1.e000604.1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.4.559"},{"key":"2025073013012278000_8.1.e000604.2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.22555"},{"key":"2025073013012278000_8.1.e000604.3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0148607116672265","article-title":"Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study","volume":"42","author":"Hvistendahl","year":"2018","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2025073013012278000_8.1.e000604.4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.9.1171"},{"key":"2025073013012278000_8.1.e000604.5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2017.11.023","article-title":"Factors associated with response to Teduglutide in patients with short-bowel syndrome and intestinal failure","volume":"154","author":"Jeppesen","year":"2018","journal-title":"Gastroenterology"},{"key":"2025073013012278000_8.1.e000604.6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2468-1253(19)30077-9","article-title":"Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial","volume":"4","author":"Naimi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073013012278000_8.1.e000604.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.7.2513"},{"key":"2025073013012278000_8.1.e000604.8","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850171486"},{"key":"2025073013012278000_8.1.e000604.9","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.061440"},{"key":"2025073013012278000_8.1.e000604.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2011.03.003"},{"key":"2025073013012278000_8.1.e000604.11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.165886"},{"key":"2025073013012278000_8.1.e000604.12","doi-asserted-by":"crossref","first-page":"E1050","DOI":"10.1152\/ajpendo.1997.272.6.E1050","article-title":"Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2","volume":"272","author":"Brubaker","year":"1997","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025073013012278000_8.1.e000604.13","unstructured":"SPC R . Revestive: summary of product characteristics, 2016."},{"key":"2025073013012278000_8.1.e000604.14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.2.166"},{"key":"2025073013012278000_8.1.e000604.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"2025073013012278000_8.1.e000604.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01723.x"},{"key":"2025073013012278000_8.1.e000604.17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.267"},{"key":"2025073013012278000_8.1.e000604.18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.370"},{"key":"2025073013012278000_8.1.e000604.19","doi-asserted-by":"publisher","DOI":"10.3109\/00365528509091665"},{"key":"2025073013012278000_8.1.e000604.20","doi-asserted-by":"publisher","DOI":"10.3109\/00365529008997596"},{"key":"2025073013012278000_8.1.e000604.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91220-3"},{"key":"2025073013012278000_8.1.e000604.22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.4.478"},{"key":"2025073013012278000_8.1.e000604.23","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00030.2005"},{"key":"2025073013012278000_8.1.e000604.24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4093\/dmj.2015.39.4.304","article-title":"Effects of sitagliptin on insulin and glucagon levels in type 2 diabetes mellitus","volume":"39","author":"Kim","year":"2015","journal-title":"Diabetes Metab J"},{"key":"2025073013012278000_8.1.e000604.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.08.017"},{"key":"2025073013012278000_8.1.e000604.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.015"},{"key":"2025073013012278000_8.1.e000604.27","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.5.701"},{"key":"2025073013012278000_8.1.e000604.28","doi-asserted-by":"publisher","DOI":"10.1039\/an9840900937"},{"key":"2025073013012278000_8.1.e000604.29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF01338151","article-title":"Neue Methode zur Bestimmung des Stickstoffs in organischen K\u00f6rpern\" (New method for the determination of nitrogen in organic substances)","volume":"22","author":"Kjeldahl","year":"1883","journal-title":"Zeitschrift f\u00fcr analytische Chemie"},{"key":"2025073013012278000_8.1.e000604.30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/00365521003611299","article-title":"Fecal fat determination with a modified titration method","volume":"45","author":"Berstad","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"2025073013012278000_8.1.e000604.31","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.6.763"},{"key":"2025073013012278000_8.1.e000604.32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0148607116655449","article-title":"Home parenteral nutrition in adult patients with chronic intestinal failure: the evolution over 4 decades in a tertiary referral center","volume":"41","author":"Brandt","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2025073013012278000_8.1.e000604.33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.9.4382"},{"key":"2025073013012278000_8.1.e000604.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01167.x"},{"key":"2025073013012278000_8.1.e000604.35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40268-014-0072-6","article-title":"Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data","volume":"14","author":"Murai","year":"2014","journal-title":"Drugs R D"},{"key":"2025073013012278000_8.1.e000604.36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1507\/endocrj.EJ14-0148","article-title":"Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes","volume":"62","author":"Otsuka","year":"2015","journal-title":"Endocr J"},{"key":"2025073013012278000_8.1.e000604.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1009"},{"key":"2025073013012278000_8.1.e000604.38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3164\/jcbn.14-111","article-title":"Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration","volume":"56","author":"Fujiwara","year":"2015","journal-title":"J Clin Biochem Nutr"},{"key":"2025073013012278000_8.1.e000604.39","unstructured":"MSD . Januvia-Summary of product characteristics, 2012."},{"key":"2025073013012278000_8.1.e000604.40","doi-asserted-by":"publisher","DOI":"10.1002\/pst.185"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2021-000604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:01:32Z","timestamp":1753905692000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2021-000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,5,11]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bmjgast-2021-000604"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2021-000604","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}